Forum Pharmaceuticals’ CIS Treatment Falls Short in Phase 3

Forum Pharmaceuticals’ encenicline missed the primary endpoint in two Phase 3 trials for cognitive impairment in schizophrenia.

Forum conducted two parallel placebo-controlled studies evaluating the alpha 7 receptor agonist in 1,500 CIS patients over 26 weeks. The trial failed to meet the primary endpoint of influencing cognitive function as measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Composite Score (MATRICS) and the interview-based Schizophrenia Cognition Rating Scale (SCoRS).